Latest From NantWorks LLC
A review of biopharma start-up deal-making and financing activity from July through September 2017, based on data from Strategic Transactions, showed that fundraising declined 18% from the previous quarter, however the number of acquisitions doubled to eight.
The Vice President’s cancer “moonshot” is a great opportunity for biopharma companies to engage in a process that should remind policymakers and the public of the promise of biomedical innovation at a time when the industry’s pricing and financial engineering activities are under scrutiny on Capitol Hill. The selection of the “blue ribbon” panel puts those two images in stark contrast.
Start-ups raised $2.41 billion in Q4 2015. Biopharma companies penned 29 alliances; seven acquisitions were signed in the biopharma and diagnostics industries.
The Administration is actively considering policy options to address prescription drug costs. But the President doesn’t want to be remembered for that.
- In Vitro Diagnostics
- Monitoring Equipment & Devices
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- NantWorks LLC
- Senior Management
- Patrick Soon-Shiong, MD, Chmn.
- Contact Info
Phone: (310) 883-1300
9920 Jefferson Blvd.
Culver City, CA 90232
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.